(VIANEWS) – Ternium S.A. Ternium S.A. (TX), Host Hotels & Resorts (HST), CBOE Holdings (CBOE) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Ternium S.A. Ternium S.A. (TX)
26.9% sales growth and 6.28% return on equity
Ternium S.A., together with its subsidiaries, manufactures and distributes steel products in Mexico, Southern Region, Brazil, and internationally. It operates through three segments: Steel, Mining, and Usiminas. The Steel segment offers slabs, hot and cold rolled products, coated products, roll formed and tubular products, bars, billets, and other products. Its Mining segment sells iron ore and pellets. The Usiminas segment offers iron ore extraction, steel transformation, and production of capital goods and logistics; and manufactures and sells various products and raw materials, such as flat steel, iron ore, and stamped steel parts for the automotive industry and products for the civil construction and capital goods industry. It also provides medical and social; scrap; renewable energy; and engineering and other services, as well as operates as a distribution company. In addition, the company engages in the exploration, exploitation, and pelletizing of iron ore. Ternium S.A. was founded in 1961 and is based in Luxembourg City, Luxembourg. Ternium S.A. is a subsidiary of Techint Holdings S.à r.l.
Earnings Per Share
As for profitability, Ternium S.A. Ternium S.A. has a trailing twelve months EPS of $3.3.
PE Ratio
Ternium S.A. Ternium S.A. has a trailing twelve months price to earnings ratio of 11.1. Meaning, the purchaser of the share is investing $11.1 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.28%.
Volume
Today’s last reported volume for Ternium S.A. Ternium S.A. is 442749 which is 66.21% above its average volume of 266369.
Sales Growth
Ternium S.A. Ternium S.A.’s sales growth is 23.3% for the ongoing quarter and 26.9% for the next.
Revenue Growth
Year-on-year quarterly revenue growth grew by 31.9%, now sitting on 18.77B for the twelve trailing months.
Yearly Top and Bottom Value
Ternium S.A. Ternium S.A.’s stock is valued at $36.64 at 06:22 EST, way below its 52-week high of $45.58 and higher than its 52-week low of $35.22.
2. Host Hotels & Resorts (HST)
8.8% sales growth and 10.49% return on equity
Host Hotels & Resorts, Inc. is an S&P 500 company and is the largest lodging real estate investment trust and one of the largest owners of luxury and upper-upscale hotels. The Company currently owns 74 properties in the United States and five properties internationally totaling approximately 46,100 rooms. The Company also holds non-controlling interests in six domestic and one international joint ventures. Guided by a disciplined approach to capital allocation and aggressive asset management, the Company partners with premium brands such as Marriott®, Ritz-Carlton®, Westin®, Sheraton®, W®, St. Regis®, The Luxury Collection®, Hyatt®, Fairmont®, Hilton®, Swissôtel®, ibis® and Novotel®, as well as independent brands. For additional information, please visit the Company's website at www.hosthotels.com.
Earnings Per Share
As for profitability, Host Hotels & Resorts has a trailing twelve months EPS of $1.02.
PE Ratio
Host Hotels & Resorts has a trailing twelve months price to earnings ratio of 17.47. Meaning, the purchaser of the share is investing $17.47 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.49%.
Yearly Top and Bottom Value
Host Hotels & Resorts’s stock is valued at $17.82 at 06:22 EST, way below its 52-week high of $21.31 and way above its 52-week low of $14.92.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Jun 28, 2024, the estimated forward annual dividend rate is 0.8 and the estimated forward annual dividend yield is 4.49%.
Volume
Today’s last reported volume for Host Hotels & Resorts is 4881250 which is 15.36% below its average volume of 5767720.
3. CBOE Holdings (CBOE)
8.2% sales growth and 21.09% return on equity
Cboe Global Markets, Inc., through its subsidiaries, operates as an options exchange worldwide. It operates through five segments: Options, North American Equities, Futures, Europe and Asia Pacific, and Global FX. The Options segment trades in listed market indices. The North American Equities segment trades in listed U.S. and Canadian equities. This segment also offers exchange-traded products (ETP) transaction and ETP listing services. The Futures segment trades in futures. The Europe and Asia Pacific segment offers pan-European listed equities and derivatives transaction services, ETPs, exchange-traded commodities, and international depository receipts, as well as ETP listings and clearing services. The Global FX segment provides institutional foreign exchange (FX) trading and non-deliverable forward FX transactions services. The company has strategic relationships with S&P Dow Jones Indices, LLC; FTSE International Limited; Frank Russell Company; MSCI Inc.; and DJI Opco, LLC. The company was formerly known as CBOE Holdings, Inc. and changed its name to Cboe Global Markets, Inc. in October 2017. Cboe Global Markets, Inc. was founded in 1973 and is headquartered in Chicago, Illinois.
Earnings Per Share
As for profitability, CBOE Holdings has a trailing twelve months EPS of $7.45.
PE Ratio
CBOE Holdings has a trailing twelve months price to earnings ratio of 22.74. Meaning, the purchaser of the share is investing $22.74 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 21.09%.
4. ResMed (RMD)
6.4% sales growth and 22.39% return on equity
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. It operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN's software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. The company was founded in 1989 and is headquartered in San Diego, California.
Earnings Per Share
As for profitability, ResMed has a trailing twelve months EPS of $6.05.
PE Ratio
ResMed has a trailing twelve months price to earnings ratio of 30.72. Meaning, the purchaser of the share is investing $30.72 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 22.39%.
Previous days news about ResMed(RMD)
- According to Zacks on Friday, 21 June, "Some better-ranked stocks in the broader medical space are Him & Hers Health (HIMS Quick QuoteHIMS – Free Report) , Medpace (MEDP Quick QuoteMEDP – Free Report) and ResMed (RMD Quick QuoteRMD – Free Report) . ", "While Hims & Hers Health sports a Zacks Rank #1 (Strong Buy), Medpace and ResMed carry a Zacks Rank #2 (Buy) each. "
- According to Zacks on Friday, 21 June, "Some better-ranked stocks in the broader medical space are Him & Hers Health (HIMS Quick QuoteHIMS – Free Report) , Medpace (MEDP Quick QuoteMEDP – Free Report) and ResMed (RMD Quick QuoteRMD – Free Report) . ", "While Hims & Hers Health sports a Zacks Rank #1 (Strong Buy), Medpace and ResMed carry a Zacks Rank #2 (Buy) each. "
- According to Zacks on Wednesday, 19 June, "Some better-ranked stocks in the broader medical space are Hims & Hers Health (HIMS Quick QuoteHIMS – Free Report) , Medpace (MEDP Quick QuoteMEDP – Free Report) and ResMed (RMD Quick QuoteRMD – Free Report) . ", "While Hims & Hers Health sports a Zacks Rank #1 (Strong Buy), Medpace and ResMed carry a Zacks Rank #2 (Buy) each. "
- According to Zacks on Thursday, 20 June, "Some better-ranked stocks in the broader medical space are Hims & Hers Health (HIMS Quick QuoteHIMS – Free Report) , Medpace (MEDP Quick QuoteMEDP – Free Report) and ResMed (RMD Quick QuoteRMD – Free Report) . ", "While Hims & Hers Health sports a Zacks Rank #1 (Strong Buy), Medpace and ResMed carry a Zacks Rank #2 (Buy) each. "
- According to Zacks on Wednesday, 19 June, "Industry participants like Boston Scientific (BSX Quick QuoteBSX – Free Report) , ResMed (RMD Quick QuoteRMD – Free Report) , Lantheus (LNTH Quick QuoteLNTH – Free Report) and Haemonetics (HAE Quick QuoteHAE – Free Report) have adapted to changing consumer preferences, and the majority of them are witnessing a rise in share price. ", "However, ResMed has been witnessing increased operating expenses over the past few quarters. "
